These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31474702)

  • 1. Evaluation of the Roflumilast Effect Supplemented with Linezolid in Pleural Empyema in Rats Caused by Intrapleural Staphylococcus aureus Inoculation.
    Kerget B; Araz Ö; Kerget F; Erol HS; Özmen S; Halıcı Z; Akgün M
    Jpn J Infect Dis; 2020 Jan; 73(1):1-7. PubMed ID: 31474702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
    Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of pleural empyema in rats by thoracentesis with intrapleural pressure monitoring.
    Schopf LF; Fraga JC; Amantéa SL; Sanches P; Muller A; Borowski S; Kulczynski J; Costa E
    Pediatr Surg Int; 2004 Jul; 20(7):515-9. PubMed ID: 15205903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
    Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
    Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition.
    Keskin H; Keskin F; Tavaci T; Halici H; Yuksel TN; Ozkaraca M; Bilen A; Halici Z
    Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1103-1110. PubMed ID: 33686709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
    Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of roflumilast on the pancreas and remote organs in a cerulein-induced experimental acute pancreatitis model in rats.
    Uslukaya O; Turkoglu A; Yazgan UC; Kaplan I; Ibiloglu I; Kapan M; Gumus M
    Surg Today; 2016 Dec; 46(12):1435-1442. PubMed ID: 26983712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
    Peng CK; Huang KL; Wu CP; Wu YK; Tzeng IS; Lan CC
    J Surg Res; 2019 Sep; 241():24-30. PubMed ID: 31004869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820
    [No Abstract]   [Full Text] [Related]  

  • 11. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
    Bateman ED; Goehring UM; Richard F; Watz H
    J Allergy Clin Immunol; 2016 Jul; 138(1):142-149.e8. PubMed ID: 26915674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
    Louw C; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbroker D; Bardin PG
    Respiration; 2007; 74(4):411-7. PubMed ID: 16954654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring.
    Ashizawa N; Tsuji Y; Kawago K; Higashi Y; Tashiro M; Nogami M; Gejo R; Narukawa M; Kimura T; Yamamoto Y
    J Infect Chemother; 2016 May; 22(5):331-4. PubMed ID: 26732509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strain.
    Chien JY; Mendes RE; Deshpande LM; Hsueh PR
    J Infect; 2017 Aug; 75(2):182-184. PubMed ID: 28506787
    [No Abstract]   [Full Text] [Related]  

  • 15. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
    Ding H; Li N; He X; Liu B; Dong L; Liu Y
    Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
    Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
    Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.